Navigation Links
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
Date:12/6/2007

SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that the Company's recently submitted IND for TG101348 is now active and the Company plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008. Additionally, TargeGen announced that a series of presentations related to TG101348 will be made at the 2007 ASH Conference (Atlanta, December 8-11, 2007) by Company scientific staff and outside academic collaborators.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

Scheduled ASH presentations include:

-- Catriona Jamieson -- Selective Inhibition of JAK2 Driven Erythroid

Differentiation of Polycythemia Vera

-- Animesh Pardanani & Ayalew Tefferi -- Primary Cell Experiments with

TG101348, A JAK2 Selective Small Molecule Inhibitor, in the Presence of

Myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12

Mutations

-- Gerlinde Wernig & Gary Gilliland -- Efficacy of TG101348, a Selective

JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced

Polycythemia Vera, Session Type

-- Betty Tam -- TG101348: A Dual Acting JAK2/FLT3 Small Molecule Kinase

Inhibitor for the Treatment of AML

-- John Hood -- Prospective Identification of Resistance Mutants to the

JAK2 Inhibitor TG101348

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V
'/>"/>

SOURCE TargeGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/21/2014)... (PRWEB) December 21, 2014 As ... alleging heart attacks, stroke and blood clots from using ... increase, a new study shows that the male hormone ... cancer. In a study published in the Proceedings of ... James Amos-Landgraf examined a group of male rats with ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and 8(a) ... VA., today announced it has been recognized by Washington ... ranks the fastest growing government contracting small businesses by calculating ... This is the first year that Concept Plus, LLC., participated ... a 95.92% compound annual growth rate. “For Concept Plus to ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 MissyDress, a ... for all prom lovers. The business has drastically cut ... prom dresses to everyone until Jan. 30, 2015. Many ... dresses, sweetheart dresses, V-neck dresses, lace dresses, and more. ... are not there every day. Whether A-line princess prom ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... of uterine cancer. According to the statistics it was found ... cases//. Hence the Brazilian government plans to test the new ... then the government plans to release the vaccine in the ... to vaccinate Brazilian women against the human Papilloma virus (HPV). ...
... is endemic to the eastern Democratic Republic of Congo where ... not diagnosed at an initial stage then proves to be ... then the patient can be completely cured with antibiotics. ... and this highly contagious disease is spreading like a wild ...
... alpha-synuclein, in the brain, in is considered to be ... a postdoctoral scientist , at the Whitehead Institute in Cambridge, ... are investigating the ways of preventing formation of these clumps, ... prevent the death of neurons, whose deterioration results in ...
... drug promises to slow down the progress of the dreadful ... 3,00,000 Americans were found to be affected by the fatal ... the skin and in many times it completely damages the ... have lung damaged more often it includes women only. ...
... in Ireland, suicide is the most popular cause of ... were 431 registered suicides in 2005,with approximately 6% of those recorded ... to the media not to sensationalize suicides, adding that ... , , “We are sensing that there is ...
... an increase rise in the obesity and diabetic rate ... in their life expectancy. //This has also pressurized the ... rates from cancer declined about 14 % and also ... that that average life expectancy for Australians, at 78 ...
Cached Medicine News:Health News:Breakthrough In Parkinson's research 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: